cancer

RGA's Dr. Radi Counsell reviews how modern immunotherapy is transforming cancer outcomes, and the real possibility that it might even cure some highly lethal cancers such as malignant melanoma

The number of people living after a cancer diagnosis (i. e. prevalent cases) has been increasing for the past 30 years, reaching around 5 % of the total population in several countries.

What if people could be screened for more types of cancer with a single test?
 

In this edition of ReCent Medical News, Monique Esterhuizen reflects on how genomics enable us to “look under the hood” of a tumor and develop the most suitable personalized treatment. Furthermore she explores what insurers need to know about these promising cancer treatments.
 

In this second interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer diagnostics.

Dr. Achim Regenauer discusses how far we are along the road to having multi-cancer early detection tests – essentially powerful liquid biopsies – in the clinical setting. It appears that this is much closer than previously assumed, and that these tests will complement, rather than replace, current detection options.
 

In this, the last of our 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of how genomic sequencing of cancers is blasting a trail for improved, early diagnosis and precision medicine by providing a powerful and ever-expanding means to detect, identify, subdivide and monitor cancer – and how this remarkable development could impact Life & Health insurers.

Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of targeted cancer therapy – a catch-all term for a spectrum of innovative new cancer therapies that are improving the outlook for patients and moving us closer to precision medicine – and its impact on Life & Health insurers.
 

Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of liquid biopsy, one of the most exciting potential advances in cancer research. With promising results to-date for certain late-stage cancers, early and painless diagnosis from liquid biopsies could have huge positive consequences for wider cancer treatments and recoveries.
 

A series of clinical trials examining biomarkers to reduce cancer deaths by around 20% could revolutionize cancer care. What does this mean for insurers?